NuMe is developing cobiotic™ products specifically designed to help people with prediabetes and unhealthy body weight manage their condition. Our cobiotic products are derived from natural bioactive ingredients in edible plants that increase the proportion of beneficial bacteria in the GI tract by promoting the growth of specific bacteria while inhibiting undesirable bacteria. Cobiotics also help create a healthy microbiota environment. The resulting shift in the bacterial population is intended to positively affect factors associated with prediabetes, including the ability to reach and maintain a healthy body weight. NuMe’s products will be supported with human clinical data demonstrating their ability to modify GI bacterial populations and improve biomarkers associated with prediabetes
The proprietary combination of ingredients in our cobiotic products is designed specifically to shift GI microbiome populations to favorably affect prediabetes by supporting healthy blood glucose (sugar) and insulin levels as well as bolstering other components of metabolic fitness such as healthy levels of satiety hormones and the appetite hormone ghrelin. NuMe’s cobiotic products are also intended to help produce a shift in the GI microbiome population in favor of bacterial strains supporting less efficient absorption of calories, a potential aid to maintaining a healthy body weight. These benefits are intended to support consumers’ efforts to eat less while obtaining greater benefit from these and other healthy lifestyle changes, with the aim of helping to achieve more healthy blood glucose levels and improved insulin sensitivity. NuMe products are expected to provide a new option for prediabetics that will support metabolic fitness, help maintain a healthy body weight and contribute to overall quality of life.
NuMe’s first product, NM504, contains a proprietary blend of prebiotic and other ingredients formulated to help prediabetic individuals achieve healthy blood glucose levels and manage their body weight by altering the composition of their GI bacteria. NM504 supports the activity of bacteria that inhibit appetite signals and stimulate satiety signals, and it also inhibits bacteria that convert undigested nutrients into extra calories. In addition, NM504 shifts the bacteria environment of the microbiome to decrease the absorption of sugar and cholesterol.
NuMe is initiating a clinical trial at a well-known center for clinical research in obesity and metabolic disease, to test the ability of NM504 to help maintain healthy blood glucose levels in prediabetics. The NM504 trial is a placebo-controlled, double-blinded, proof-of-concept study that will test the ability of two different doses of NM504 to alter the human microbiome and improve insulin sensitivity and fasting blood glucose levels in prediabetic individuals. It will also assess blood biomarkers associated with GI and metabolic health, relevant safety parameters and GI bacterial changes consistent with the expected mechanism of action of NM504.